Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

dolutegravir

This page shows the latest dolutegravir news and features for those working in and with pharma, biotech and healthcare.

Gilead’s latest Biktarvy data offers hope to HIV patients

Gilead’s latest Biktarvy data offers hope to HIV patients

a dolutegravir-containing regimen. ... These outcomes were reported in participants 96 weeks after switching to open-label Biktarvy following 144 weeks of blinded dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs).

Latest news

  • GSK considers more divestments to help R&D push GSK considers more divestments to help R&D push

    HIV sales through the ViiV Healthcare joint venture showed signs of weakness, as Tivicay (dolutegravir) continued to decline in the face of strong competition from Gilead Sciences, particularly its fast-growing ... There was an acceleration in sales of

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing ... diagnosed patients and Juluca

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay (dolutegravir) and the nucleoside reverse transcriptase inhibitor lamivudine – is integral to the company’s attempt to muscle out ... Dovato is the second

  • Shingrix lifts GSK in Q1, but two more vaccines are culled Shingrix lifts GSK in Q1, but two more vaccines are culled

    The bulk of GSK’s HIV sales come from its dolutegravir-based combination products Tivicay and Triumeq, but greater competition in the market from arch-rival Gilead Sciences with new products ... GSK is looking to a series of new two-drug HIV drugs to

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    Meanwhile, Dovato (dolutegravir/lamivudine) developed by GSK-led joint venture ViiV, is the first ever once-a-day two-drug STR for treatment-naïve patients.

More from news
Approximately 6 fully matching, plus 51 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...

Quick links